Literature DB >> 34334544

Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study.

Kyeong-Hyeon Chun1, Jung Mi Park2, Chan Joo Lee1, Jaewon Oh1, Sungha Park1, Seok-Min Kang1, Sang-Hak Lee1.   

Abstract

AIMS: Mismatches between the risk status of a patient and coronary imaging data can lead to conflicting strategies to prevent a cardiovascular event. We evaluated whether statin use was associated with cardiovascular benefit in high-risk individuals whose coronary computed tomography angiography (CCTA) results showed normal coronary arteries.
METHODS: Among asymptomatic individuals whose CCTA showed normal or near normal coronary arteries, 3,389 persons with high- or very-high-risk status were included in this retrospective study. After 1:2 propensity score matching, 906 individuals (302 new statin users and 604 controls; mean age 61 years; male 58%) were analysed. The primary outcome variable was major adverse cardiovascular and cerebrovascular events (MACCEs) that consisted of cardiovascular death, nonfatal myocardial infarction, coronary revascularisation, and nonfatal ischemic stroke.
RESULTS: At a median follow-up of 5.8 years, 20 statin users and 17 controls (7.4 and 5.6 events/1,000 person-year, respectively; hazard ratio [HR) 1.04; p=0.92) experienced MACCE. Kaplan-Meier curves showed similar MACCE rates in both groups (p=0.91). In separate analyses for persons with normal (p=0.29) or near normal coronary arteries (p=0.67), MACCE rates did not differ between the groups. Age (HR 1.04; p=0.044), male sex (HR 3.06, p=0.018), and smoking (HR 2.87, p=0.019) were independently associated with MACCEs. In subgroup analyses, no significant factors affected the relationship between statin use and MACCEs.
CONCLUSIONS: Statin use was not associated with cardiovascular risk reduction in high-risk persons with normal or near normal coronary arteries. More individualised lipid-lowering therapy may benefit this population.

Entities:  

Keywords:  Coronary artery disease; Health care; Hydroxymethylglutaryl-CoA reductase inhibitors; Outcome assessment; Risk factors

Mesh:

Substances:

Year:  2021        PMID: 34334544      PMCID: PMC9252647          DOI: 10.5551/jat.63004

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.394


  15 in total

1.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  J Am Coll Cardiol       Date:  2018-11-10       Impact factor: 24.094

2.  Statin therapy is associated with lower all-cause mortality in patients with non-obstructive coronary artery disease.

Authors:  In-Chang Hwang; Joo-Yeong Jeon; Younhee Kim; Hyue Mee Kim; Yeonyee E Yoon; Seung-Pyo Lee; Hyung-Kwan Kim; Dae-Won Sohn; Jidong Sung; Yong-Jin Kim
Journal:  Atherosclerosis       Date:  2015-01-31       Impact factor: 5.162

3.  Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) registry.

Authors:  Benjamin J W Chow; Gary Small; Yeung Yam; Li Chen; Ruth McPherson; Stephan Achenbach; Mouaz Al-Mallah; Daniel S Berman; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Victor Y Cheng; Kavitha Chinnaiyan; Ricardo Cury; Augustin Delago; Allison Dunning; Gundrun Feuchtner; Martin Hadamitzky; Jörg Hausleiter; Ronald P Karlsberg; Philipp A Kaufmann; Yong-Jin Kim; Jonathon Leipsic; Troy LaBounty; Fay Lin; Erica Maffei; Gilbert L Raff; Leslee J Shaw; Todd C Villines; James K Min
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-12       Impact factor: 8.311

4.  A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study.

Authors:  Martin Bødtker Mortensen; Valentin Fuster; Pieter Muntendam; Roxana Mehran; Usman Baber; Samantha Sartori; Erling Falk
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

5.  Risk Reclassification With Coronary Computed Tomography Angiography-Visualized Nonobstructive Coronary Artery Disease According to 2018 American College of Cardiology/American Heart Association Cholesterol Guidelines (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes : An International Multicenter Registry [CONFIRM]).

Authors:  Donghee Han; Ashley Beecy; Khalil Anchouche; Heidi Gransar; Patricia C Dunham; Ji-Hyun Lee; Stephan Achenbach; Mouaz H Al-Mallah; Daniele Andreini; Daniel S Berman; Jeroen J Bax; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo C Cury; Augustin DeLago; Gudrun Feuchtner; Martin Hadamitzky; Joerg Hausleiter; Philipp A Kaufmann; Yong-Jin Kim; Jonathon A Leipsic; Erica Maffei; Hugo Marques; Pedro de Araújo Gonçalves; Gianluca Pontone; Gilbert L Raff; Ronen Rubinshtein; Todd C Villines; Yao Lu; Jessica M Peña; Leslee J Shaw; James K Min; Fay Y Lin
Journal:  Am J Cardiol       Date:  2019-08-23       Impact factor: 2.778

6.  Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Khurram Nasir; Marcio S Bittencourt; Michael J Blaha; Ron Blankstein; Arthur S Agatson; Juan J Rivera; Michael D Miedema; Michael D Miemdema; Christopher T Sibley; Leslee J Shaw; Roger S Blumenthal; Matthew J Budoff; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2015-10-13       Impact factor: 24.094

7.  Absence of coronary artery calcification and all-cause mortality.

Authors:  Michael Blaha; Matthew J Budoff; Leslee J Shaw; Faisal Khosa; John A Rumberger; Daniel Berman; Tracy Callister; Paolo Raggi; Roger S Blumenthal; Khurram Nasir
Journal:  JACC Cardiovasc Imaging       Date:  2009-06

8.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

9.  Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease.

Authors:  Michelle C Williams; Amanda Hunter; Anoop S V Shah; Valentina Assi; Stephanie Lewis; Joel Smith; Colin Berry; Nicholas A Boon; Elizabeth Clark; Marcus Flather; John Forbes; Scott McLean; Giles Roditi; Edwin J R van Beek; Adam D Timmis; David E Newby
Journal:  J Am Coll Cardiol       Date:  2016-04-19       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.